Full Press Release Details
ENTINOSTAT DATA TO BE HIGHLIGHTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2016 ANNUAL MEETING
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused
on developing entinostat in multiple cancer indications, today announced that clinical data from the National Cancer Institute s Cancer Therapy Evaluation Program (NCI-CTEP) will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from June 3 to June 7, 2016 in Chicago, Illinois.
Preliminary results from ENCORE-601, a Phase 1b/2, open-label trial evaluating entinostat in combination with Keytruda (pembrolizumab) in non-small cell lung cancer and melanoma patients are available as a published abstract only at abstract.asco.org. Clinical results highlight entinostat s potential use in
combination approaches to treat various cancers.
Details of the two investigator-sponsored poster presentations and the one company-sponsored abstract
Poster Session: Breast Cancer HER2/ER
and Time: Sunday, June 5, 8:00 AM 11:30 AM, Central time
Abstract Number: 609
Presenter: Bora Lim, MD Anderson Cancer Center
Poster Session: Genitourinary (nonprostate) cancer
Date and Time: Monday, June 6, 1:00 PM 4:30 PM, Central time
Abstract Number: 4560
Presenter: Roberto Pili, Indiana University
Abstract Number: e20659
Lead Author: Melissa Johnson, Sarah Cannon Research Institute
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical
stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Entinostat, which was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from
our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer. Concurrently, Syndax is developing entinostat with a focus on tumors that have shown sensitivity
to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially
enhancing the body s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for
TNBC,with Pfizer Inc. and Merck KGaA, Darmstadt, Germany for ovarian cancer. For more information on Syndax please visit www.syndax.com.
Syndax s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as
may, will, expect, plan, anticipate, estimate, intend, believe and similar expressions (as well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax s expectations and assumptions as of the date of this press release. Each of these forward-looking statements
involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, the reporting of clinical data for
Syndax s product candidate and its potential use to treat various
cancers. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical
trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Syndax s collaborators to support or advance collaborations or product
candidates and unexpected litigation or other disputes. Other factors that may cause Syndax s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax s
filings with the U.S. Securities and Exchange Commission, including the Risk Factors sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes available.
Investor and Media Contacts